How would you approach adjuvant therapy for a high-risk stage III colon cancer which is MSI-high in a patient >70 years of age?

Benefit of oxaliplatin in patients >70 years of age is not proven and only 5FU/capecitabine in a MSI-H tumor is of questionable efficacy. What would be the best regimen in this scenario?

Answer from: Medical Oncologist at Academic Institution

First, MSI-H stage III colon cancer patients will benefit from oxaliplatin-based adjuvant chemotherapy (Jin et al., PMID 33467526). This is different from stage II MSI-H colon cancer (we do not recommend adjuvant chemotherapy for these patients). Second, oxaliplatin seemed to be an important co...

Comments

Medical Oncologist at Harvard Medical School
We also have a trial after adjuvant chemo (can be ...

Please select the option that best describes you:

How would you approach adjuvant therapy for a high-risk stage III colon cancer which is MSI-high in a patient >70 years of age?

Related Questions